Accessibility Menu
ALK-Abelló A/s logo

ALK-Abelló A/s(OTC) AKBLF

Market Cap$8.41BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2007)-66%
5 Year+57%
1 Year+29%
1 Month-7%
$37.92
+0.00%
+0.00Today
ALK-Abelló A/s last closing stock price
MetricPriceDate
Last closeUSD 37.922026-07-16
ALK-Abelló A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.73%USD 40.652026-06-24
1 month-6.73%USD 40.652026-06-16
3 month+20.94%USD 31.352026-04-17
Year to date+5.84%USD 35.822025-12-30
1 year+29.43%USD 29.292025-07-07
3 year+257.08%USD 10.622023-07-14
5 year+56.91%USD 24.162021-07-02
Since inception-65.53%USD 110.002007-12-31

ALK-Abelló A/s Financials at a Glance

Market Cap

$8.41BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

DKK 6.82B

Net Income (TTM)

DKK 1.35B

EPS (TTM)

$0.96

P/E Ratio

39.68

Dividend

$0.25

Beta (Volatility)

0.03 (Low)

Price

$37.92

Volume

100

Open

$37.92

Previous Close

$37.92

Daily Range

$37.92 - $37.92

52-Week Range

$28.95 - $40.65

Estimated Earnings Date

Nov 17, 2026

AKBLF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ALK-Abelló A/s

ALK-Abelló A/S is a global pharmaceutical company based in Hørsholm, Denmark, specializing in allergy treatment. Established in 1923, the company offers a wide range of immunotherapy products and diagnostic tools aimed at addressing various allergies.

Products and Services
  • Immunotherapy products including injections, sublingual drops, and oral tablets
  • Adrenaline auto-injectors for severe allergic reactions
  • Diagnostic tools for identifying allergic conditions
Growth Outlook
  • Revenue increased to DKK 1.77 billion in Q1 2026, reflecting strong demand
  • Net income rose to DKK 437 million in Q1 2026, showcasing profitability
  • Continued investment in R&D to enhance product offerings and market reach
Financial Highlights
  • Trailing twelve months (TTM) revenue of DKK 6.67 billion, indicating robust growth
  • Net profit margin of 19.5% TTM, demonstrating effective cost management
  • Operating cash flow of DKK 761 million in Q1 2026, supporting financial stability
ALK-Abelló A/S operates in the biotechnology sector, focusing on innovative solutions for allergy sufferers. The company’s diverse product portfolio includes well-known treatments such as GRAZAX and RAGWITEK, which target allergic rhinitis and asthma. The recent financial performance highlights a strong upward trend in revenue and profitability, driven by increased demand for allergy treatments. The company's commitment to research and development positions it well for future growth, as it seeks to expand its market presence and enhance its product offerings. With a solid financial foundation and a focus on innovation, ALK-Abelló A/S presents a compelling opportunity for potential investors interested in the healthcare sector.
AI Generated • Aug 15, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

2,721

CEO

Peter Halling

Website

www.alk.net

Headquarters

Horsholm, CR 2970, DK

AKBLF Financials

Key Financial Metrics (TTM)

Gross Margin

68.03%

Operating Margin

26.71%

Net Income Margin

19.86%

Return on Equity

20.76%

Return on Capital

24.23%

Return on Assets

13.94%

Earnings Yield

2.52%

Dividend Yield

0.65%

Payout Ratio

26.18%

Stock Overview

Market Cap

$8.41BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

221.88M

Volume

100

Avg. Volume

49.547

Financials (TTM)

Gross Profit

DKK 4.64B

Operating Income

DKK 1.82B

EBITDA

DKK 2.17B

Operating Cash Flow

DKK 2.16B

Capital Expenditure

-DKK 273.67M

Free Cash Flow

DKK 1.88B

Cash & ST Invst.

DKK 1.73B

Total Debt

DKK 420.50M

ALK-Abelló A/s Performance Analysis

ALK-Abelló A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31DKK 637,273,2912.4%
20232023-12-31DKK 699,946,3289.8%
20242024-12-31DKK 802,990,19814.7%
20252025-12-31DKK 954,482,81018.9%
ALK-Abelló A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-300.2%
Q42025-12-3113.0%
Q12026-03-312.5%
Q22026-06-300.9%
ALK-Abelló A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31DKK 0.2135.7%
20232023-12-31DKK 0.3249.1%
20242024-12-31DKK 0.5367.4%
20252025-12-31DKK 0.8253.0%
ALK-Abelló A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3016.7%
Q42025-12-31-13.6%
Q12026-03-3161.2%
Q22026-06-30-23.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

DKK 1.79B

+17.1%

Gross Profit

DKK 1.19B

+19.7%

Gross Margin

66.57%

N/A

Market Cap

$8.41BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.09M

N/A

Employees

2,721

N/A

Net Income

DKK 337.79M

+28.4%

EBITDA

DKK 529.11M

+17.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

DKK 1.73B

+239.8%

Total Debt

DKK 420.50M

-29.0%

Accounts Receivable

DKK 1.32B

+21.3%

Inventory

DKK 1.83B

+6.4%

Long Term Debt

DKK 360.71M

-13.1%

Short Term Debt

DKK 59.79M

-66.2%

Return on Assets

13.94%

N/A

Return on Invested Capital

22.09%

N/A

Free Cash Flow

DKK 242.14M

+13.1%

Operating Cash Flow

DKK 287.97M

-10.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GNGBFGetinge AB (publ)
$25.00+0.00%
CAMRFCamurus AB
$61.75+0.00%
ZLDPFZealand Pharma A/S
$47.64+0.72%
CLCGYClicks Group Limited
$25.63+0.95%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
NVDANvidia
$228.45+0.02%
SPCXSpace Exploration Technologies
$149.74+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$11.01+0.06%

Questions About AKBLF

What is the current price of ALK-Abelló A/s?

ALK-Abelló A/s is trading at $37.92 per share.

What is the 52-week range for ALK-Abelló A/s?

Over the past 52 weeks, ALK-Abelló A/s has traded between $28.95 and $40.65.

How much debt does ALK-Abelló A/s have?

As of the most recent reporting period, ALK-Abelló A/s reported total debt of DKK 64.55M.

How much cash does ALK-Abelló A/s have on hand?

ALK-Abelló A/s reported DKK 265.52M in cash and cash equivalents in its most recent financial results.

What is ALK-Abelló A/s’s dividend yield?

ALK-Abelló A/s currently has a dividend yield of 0.65%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services